JP2008542296A5 - - Google Patents

Download PDF

Info

Publication number
JP2008542296A5
JP2008542296A5 JP2008513752A JP2008513752A JP2008542296A5 JP 2008542296 A5 JP2008542296 A5 JP 2008542296A5 JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008542296 A5 JP2008542296 A5 JP 2008542296A5
Authority
JP
Japan
Prior art keywords
composition
sirtuin
prodrug
modulator
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513752A
Other languages
Japanese (ja)
Other versions
JP2008542296A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/020406 external-priority patent/WO2006127987A2/en
Publication of JP2008542296A publication Critical patent/JP2008542296A/en
Publication of JP2008542296A5 publication Critical patent/JP2008542296A5/ja
Pending legal-status Critical Current

Links

Claims (39)

シクロデキストリンおよびサーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む組成物であって、該組成物が液体であり、かつ該サーチュインモジュレーターがレスベラトロールである場合に、該組成物は、少なくとも３０ｍＭのサーチュインモジュレーターを含む、組成物。 A composition comprising a cyclodextrin and a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof, wherein the composition is a liquid and the sirtuin modulator is resveratrol; The composition comprises at least 30 mM sirtuin modulator. 前記シクロデキストリンは、置換シクロデキストリンである、請求項１に記載の組成物。 The composition of claim 1, wherein the cyclodextrin is a substituted cyclodextrin. 前記シクロデキストリンは、グリコピラノース部分の２−ヒドロキシル基、３−ヒドロキシル基または６−ヒドロキシル基において置換される、請求項２に記載の組成物。 The composition of claim 2, wherein the cyclodextrin is substituted at the 2-hydroxyl group, 3-hydroxyl group or 6-hydroxyl group of the glycopyranose moiety. 前記シクロデキストリンは、非結晶である、請求項２に記載の組成物。 The composition of claim 2, wherein the cyclodextrin is amorphous. 前記シクロデキストリンは、ヒドロキシプロピル−β−シクロデキストリンである、請求項２に記載の組成物。 The composition of claim 2, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin. 前記サーチュインモジュレーターは、サーチュイン活性化剤である、請求項１に記載の組成物。 The composition of claim 1, wherein the sirtuin modulator is a sirtuin activator. 前記サーチュイン活性化剤は、レスベラトロール、そのアナログ、またはレスベラトロールもしくはそのアナログのプロドラッグである、請求項６に記載の組成物。 7. The composition of claim 6, wherein the sirtuin activator is resveratrol, an analog thereof, or a prodrug of resveratrol or an analog thereof. 前記サーチュイン活性化剤は、ニコチンアミドリボシド、そのアナログ、またはニコチンアミドリボシドもしくはそのアナログのプロドラッグである、請求項６に記載の組成物。 7. The composition of claim 6, wherein the sirtuin activator is nicotinamide riboside, an analog thereof, or a prodrug of nicotinamide riboside or an analog thereof. 前記組成物は、液体である、請求項１の組成物。 The composition of claim 1, wherein the composition is a liquid. 前記液体は、少なくとも３０ｍＭの前記サーチュインモジュレーターを含む、請求項９に記載の組成物。 The composition of claim 9, wherein the liquid comprises at least 30 mM of the sirtuin modulator. 前記液体は、少なくとも１００ｍＭの前記サーチュインモジュレーターを含む、請求項１０に記載の組成物。 11. The composition of claim 10, wherein the liquid comprises at least 100 mM of the sirtuin modulator. 前記組成物は、凍結乾燥粉末である、請求項１の組成物。 The composition of claim 1, wherein the composition is a lyophilized powder. シクロデキストリンおよびサーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、視覚機能障害を処置するための組成物。 Cyclodextrin and sirtuin modulator or a pharmaceutically acceptable salt thereof, including a prodrug or metabolite derivatives, compositions for treating vision impairment. サーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、速溶錠。 A fast dissolving tablet comprising a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. 前記錠剤は、１分間未満の経口溶解速度を有する、請求項１４に記載の速溶錠。 15. The fast dissolving tablet of claim 14, wherein the tablet has an oral dissolution rate of less than 1 minute. 前記錠剤は、３０秒間未満の経口溶解速度を有する、請求項１５に記載の速溶錠。 16. A fast dissolving tablet according to claim 15, wherein the tablet has an oral dissolution rate of less than 30 seconds. 前記錠剤は、２Ｓｔｒｏｎｇ−Ｃｏｂｂ単位〜６Ｓｔｒｏｎｇ−Ｃｏｂｂ単位の硬度を有する、請求項１４に記載の速溶錠。 15. The fast dissolving tablet according to claim 14, wherein the tablet has a hardness of 2 Strong-Cobb units to 6 Strong-Cobb units. 前記サーチュインモジュレーターは、サーチュイン活性化剤である、請求項１４に記載の速溶錠。 The fast-dissolving tablet according to claim 14, wherein the sirtuin modulator is a sirtuin activator. 前記サーチュイン活性化剤は、レスベラトロール、そのアナログ、またはレスベラトロールもしくはそのアナログのプロドラッグである、請求項１８に記載の速溶錠。 19. The fast dissolving tablet according to claim 18, wherein the sirtuin activator is resveratrol, an analog thereof, or a prodrug of resveratrol or an analog thereof. 前記サーチュイン活性化剤は、ニコチンアミドリボシド、そのアナログ、またはニコチンアミドリボシドもしくはそのアナログのプロドラッグである、請求項１８に記載の速溶錠。 19. The fast dissolving tablet according to claim 18, wherein the sirtuin activator is nicotinamide riboside, an analog thereof, or a prodrug of nicotinamide riboside or an analog thereof. サーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、視覚機能障害を処置するための速溶錠。 Sa over Ju-in modulator, or a pharmaceutically acceptable salt, including a prodrug or metabolite derivative, fast to treat visual impairment coated tablets. サーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、移植可能なデバイス。 An implantable device comprising a sirtuin modulator, or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof. 前記デバイスは、眼に対する移植に適している、請求項２２に記載のデバイス。 The device of claim 22, wherein the device is suitable for implantation into the eye. 前記デバイスは、生分解性である、請求項２２に記載のデバイス。 24. The device of claim 22, wherein the device is biodegradable. 前記デバイスは、前記サーチュインモジュレーターを少なくとも１ヶ月間にわたって放出する、請求項２２に記載のデバイス。 23. The device of claim 22, wherein the device releases the sirtuin modulator for at least a month. 上記デバイスは、前記サーチュインモジュレーターを少なくとも１年間にわたって放出する、請求項２５に記載のデバイス。 26. The device of claim 25, wherein the device releases the sirtuin modulator for at least one year. 前記デバイスは、前記サーチュインモジュレーターを６ヶ月間〜２年間にわたって放出する、請求項２５に記載のデバイス。 26. The device of claim 25, wherein the device releases the sirtuin modulator over a period of 6 months to 2 years. 前記サーチュインモジュレーターは、サーチュイン活性化剤である、請求項２２に記載のデバイス。 23. The device of claim 22, wherein the sirtuin modulator is a sirtuin activator. 前記サーチュイン活性化剤は、レスベラトロール、そのアナログ、またはレスベラトロールもしくはそのアナログのプロドラッグである、請求項２８に記載のデバイス。 30. The device of claim 28, wherein the sirtuin activator is resveratrol, an analog thereof, or a prodrug of resveratrol or an analog thereof. 前記サーチュイン活性化剤は、ニコチンアミドリボシド、そのアナログ、またはニコチンアミドリボシドもしくはそのアナログのプロドラッグである、請求項２８に記載のデバイス。 29. The device of claim 28, wherein the sirtuin activator is nicotinamide riboside, an analog thereof, or a prodrug of nicotinamide riboside or an analog thereof. サーチュインモジュレーター、またはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、視覚機能障害を処置するための移植可能なデバイス。 Sa over Ju-in modulator, or a pharmaceutically acceptable salt, including a prodrug or metabolite derivative, an implantable device for treating a visual impairment. 微粉化されたサーチュインモジュレーターまたはその薬学的に可能な塩、プロドラッグもしくは代謝誘導体を含む薬学的組成物であって、該微粉化されたサーチュインモジュレーターの粒子は、約３０ミクロン未満の平均直径を有する、薬学的組成物。 A pharmaceutical composition comprising a micronized sirtuin modulator or a pharmaceutically acceptable salt, prodrug or metabolic derivative thereof, wherein the particles of the micronized sirtuin modulator have an average diameter of less than about 30 microns , Pharmaceutical composition. 前記微粉化されたサーチュインモジュレーターの粒子は、約１０ミクロン未満の平均直径を有する、請求項３２に記載の薬学的組成物。 34. The pharmaceutical composition of claim 32, wherein the micronized sirtuin modulator particles have an average diameter of less than about 10 microns. 前記微粉化されたサーチュインモジュレーターの粒子は、約１ミクロン〜約５ミクロンの平均直径を有する、請求項３３に記載の薬学的組成物。 34. The pharmaceutical composition of claim 33, wherein the micronized sirtuin modulator particles have an average diameter of about 1 micron to about 5 microns. 前記微粉化されたサーチュインモジュレーターの粒子は、約１ミクロン〜約２ミクロンの平均直径を有する、請求項３４に記載の薬学的組成物。 35. The pharmaceutical composition of claim 34, wherein the micronized sirtuin modulator particles have an average diameter of about 1 micron to about 2 microns. 前記組成物は、は自由流動性の液体である、請求項３２に記載の薬学的組成物。 33. The pharmaceutical composition of claim 32, wherein the composition is a free flowing liquid. 前記組成物は、固体投薬形態である、請求項３２に記載の薬学的組成物。 35. The pharmaceutical composition of claim 32, wherein the composition is a solid dosage form. 前記粒子は、エアジェット微粉化によって形成される、請求項３２に記載の薬学的組成物。 34. The pharmaceutical composition of claim 32, wherein the particles are formed by air jet micronization. 微粉化されたサーチュインモジュレーターまたはその薬学的に許容される塩、プロドラッグもしくは代謝誘導体を含む、視覚機能障害を処置するための組成物であって、該微粉化されたサーチュインモジュレーターの粒子は、約３０ミクロン未満の平均直径を有する、組成物。 Finely powdered been sirtuin modulator or a pharmaceutically acceptable salt thereof, prodrugs or metabolic derivatives, a composition for treating visual impairment, the particles of the sirtuin modulator that is micronized, A composition having an average diameter of less than about 30 microns.
JP2008513752A 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin activators Pending JP2008542296A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US73155005P 2005-10-28 2005-10-28
US78835806P 2006-03-30 2006-03-30
PCT/US2006/020406 WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Publications (2)

Publication Number Publication Date
JP2008542296A JP2008542296A (en) 2008-11-27
JP2008542296A5 true JP2008542296A5 (en) 2009-06-18

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513752A Pending JP2008542296A (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin activators

Country Status (5)

Country Link
EP (1) EP1928440A2 (en)
JP (1) JP2008542296A (en)
AU (1) AU2006249816A1 (en)
CA (1) CA2609549A1 (en)
WO (1) WO2006127987A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
CN105732745A (en) 2007-10-25 2016-07-06 森普拉制药公司 Process for the preparation of macrolide antibacterial agents
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
WO2010003048A1 (en) 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
MX2011003373A (en) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinone, quinolone and related analogs as sirtuin modulators.
PL2393476T3 (en) * 2009-02-04 2016-07-29 Dsm Ip Assets Bv Resveratrol compositions
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
RU2550821C2 (en) 2009-10-29 2015-05-20 Сертрис Фармасьютикалз, Инк. Bicyclic pyridines and analogues as sirtuin modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
JP6170047B2 (en) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド Apoptosis-targeting nanoparticles
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
JP6208742B2 (en) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド Parenteral formulations for administering macrolide antibiotics
JP5955750B2 (en) * 2012-11-20 2016-07-20 株式会社東洋新薬 Skin preparation
EP4233878A1 (en) * 2013-03-15 2023-08-30 Washington University Administration of nicotinamide mononucleotide in the treatment of dry eye
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2017004100A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US20160374908A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
BR112018013757B1 (en) 2016-01-11 2021-11-09 The Procter & Gamble Company METHOD FOR THE TREATMENT OF A SKIN CONDITION AND COMPOSITIONS FOR IT
CN117482102A (en) 2016-02-18 2024-02-02 伊维萨股份有限公司 Method of using 5' -adenosyl-biphosphate (ADPR)
JP7090336B2 (en) * 2016-08-08 2022-06-24 慶應義塾 Utilization of NAD-related metabolites
EP3513795B1 (en) * 2016-09-13 2023-07-19 Megumi Tanaka Visual function improvement agent, and method for improving visual function
KR102116303B1 (en) * 2016-11-14 2020-05-29 밍우 왕 Formulations and related methods for treating ocular surface diseases
EP3592364A1 (en) * 2017-03-07 2020-01-15 Cempra Pharmaceuticals, Inc. Compositions and methods for treating dry eye diseases
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company Composition and method for improving the appearance of skin
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
WO2020262497A1 (en) * 2019-06-25 2020-12-30 千寿製薬株式会社 Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr)
CN115843238A (en) 2020-06-01 2023-03-24 宝洁公司 Method for improving penetration of vitamin b3 compounds into the skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2017808A6 (en) * 1988-01-19 1991-03-01 Moses Judah Folkman Growth inhibiting agent and the use thereof.
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (en) * 1999-03-31 2000-12-12 Sunstar Inc Stabilization of stilbenic compound and plant extract containing the same, and food, medicine, cosmetic or oral cavity preparation stably compounded with stilbenic compound and plant extract containing the same
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ES2190771B2 (en) * 2002-01-24 2004-03-01 Univ Alicante PROCEDURE FOR THE PRODUCTION OF RESVERATROL IN CELL CULTURES.
JP2003252760A (en) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp Therapeutic agent and/or prophylactic agent for retinal disease
CN1220486C (en) * 2002-11-15 2005-09-28 董英杰 resveratrol , piceid and its derivative and its preparation
EP1621199B8 (en) * 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
CN1925862A (en) * 2003-10-10 2007-03-07 雷斯弗洛吉克斯公司 Treatment of diseases associated with the EGR-1 enhancer element
DE102004002787A1 (en) * 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid complexes
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
JP2008527002A (en) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Similar Documents

Publication Publication Date Title
JP2008542296A5 (en)
ES2792800T3 (en) Methods of delivery of a health care active substance by administering personal health care items comprising a filament
CA2821756C (en) Sublingual films comprising apomorphine and an organic base
AU2011244783B2 (en) Pharmaceutical compositions
TW201117815A (en) Orally administered corticosteroid compositions
JP5750847B2 (en) Particulate pharmaceutical composition for oral administration of atorvastatin
HRP20130961T1 (en) Compositions for treating cancer
HRP20220929T3 (en) Inhalation composition containing aclidinium for treatment of asthma
JP2009518293A5 (en)
JP2009529538A5 (en)
KR20100119539A (en) Orally disintegrating tablets comprising diphenhydramine
HRP20220332T1 (en) Pharmaceutical composition comprising drospirenone for use as a contraceptive
NZ620879A (en) A novel formulation of indomethacin
Korani et al. Parenteral systems for statin delivery: a review
AR021443A1 (en) FORMULATION OF CONTROLLED RELEASE OF DIVALPROEX SODIUM
HRP20150811T1 (en) Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics
JP5174909B2 (en) Composition for producing an orally disintegrating dosage form in which the coating film of the active ingredient is protected
JP2007529564A5 (en)
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
RU2006137329A (en) DISSOLVING TABLETS CONTAINING LICARBAZEPINE
JP2016535794A (en) Rapidly disintegrating preparations and methods of use
KR20090015103A (en) Phenylephrine pulsed release formulations and pharmaceutical compositions
NO20065657L (en) Film-shaped ostriol-containing drug for oral administration
JP2012041293A (en) Intraoral collapsible tablet containing lactobacillus or extracted ingredient thereof
CN101015519B (en) Loratadine oral compound medication composition